



LKT Laboratories, Inc.

Olaparib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lctlabs.com
Web: lctlabs.com

Product Information

Product ID O4402

CAS No. 763113-22-0

Chemical Name

Synonym AZD2281, KU-0059436

Formula $C_{24}H_{23}FN_4O_3$

Formula Wt. 434.47

Melting Point


Purity $\geq 98\%$

Solubility DMSO (10 mg/ml), DMF (3 mg/ml)

Store Temp 4°C

Ship Temp Ambient

Description Olaparib is an inhibitor of poly(ADP-ribose) polymerase (PARP 1/2) that prevents DNA repair. Olaparib displays benefit in clinical trials of BRCA mutation-harboring ovarian and breast cancers as well as prostate, pancreatic, and non-small cell lung cancers (NSCLC). In animal models with ovarian cancer xenografts, olaparib increases apoptosis and decreases proliferation to inhibit tumor growth.



Bulk quantities available upon request

Product ID	Size
O4402	5 mg
O4402	10 mg
O4402	25 mg

References Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. *Ann Oncol.* 2013 Nov 12. [Epub ahead of print]. PMID: 24225019.

Olaparib Enters Phase III Clinical Testing. *Cancer Discov.* 2013 Nov;3(11):1210. PMID: 24203936.

Postel-Vinay S, Bajrami I, Friboulet L, et al. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. *Oncogene.* 2013 Nov 21;32(47):5377-87. PMID: 23934192.

Kortmann U, McAlpine JN, Xue H, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. *Clin Cancer Res.* 2011 Feb 15;17(4):783-91. PMID: 21097693.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.